Antiulcer prostaglandin misoprostol: single and multiple dose pharmacokinetic profile.

  title={Antiulcer prostaglandin misoprostol: single and multiple dose pharmacokinetic profile.},
  author={A. Karim},
  volume={33 Suppl},
  • A. Karim
  • Published 1987
  • Medicine
  • Prostaglandins
Low misoprostol dose (microgram range), extremely low plasma levels (pg range) of misoprostol acid, and the necessity of using a complex, time consuming, and labor intensive RIA method of analysis make it technically difficult to study the pharmacokinetic profile of misoprostol in man. The clinical relevance of the misoprostol pharmacokinetic data should be interpreted with care in view of the combined local and systemic effects of the drug. The studies presented in the present review indicate… Expand
The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration.
Misoprostol acid is secreted in colostrum within 1h of oral administration of 600 microg of misoprostols; the pharmacokinetics of misobrostol after oral administration during postpartum is similar to that of other pregnancy periods. Expand
Pharmacokinetics of Diclofenac and Misoprostol When Administered Alone or as a Combination Product
Diclofenac and misoprostol may be given in a combination dosage form without either drug altering the pharmacokinetics of the other. Expand
Oral misoprostol is rapidly absorbed in postpartum women at term
  • K. L. Andolina, J. Tolosa, J. M. Monzo, N. Roberts, S. Daly
  • Medicine
  • The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2003
Oral misoprostol is rapidly absorbed and bioavailable in the post partum period and may prove useful in postpartum management, according to the novel packaging of misopostol in capsule form. Expand
Disposition of Misoprostol and its Active Metabolite in Patients With Normal and Impaired Renal Function
The dose of misoprostol may need to be reduced in ESRD patients on prolonged hemodialysis to prevent unnecessary high plasma levels of misobrostol acid and to avoid possible dose‐related adverse effects. Expand
Misoprostol: Discovery, development, and clinical applications
Misoprostol effectively heals and prevents NSAID-induced gastropathy, a therapeutic need previously unserved, and may have advantages over antisecretory drugs in the compromised patient who is a chronic smoker or alcohol user, in refractory duodenal ulcer patients, in recurrent ulcer, and in emergency use for acute upper GI bleeding. Expand
Determination of misoprostol acid in plasma samples by UPLC-MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor.
This method presented high sensitivity, being able to quantify MA in plasma samples following a low 25 μg misoprostol administered vaginally aimed to induce labor in parturients women. Expand
Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec.
Pharmacokinetic and bioavailability studies of the combination product taken separately and together reveal a high between- and within-subject variability in plasma diclofenac levels, especially when the enteric-coated tablets were given after food. Expand
Misoprostol : Pharmacokinetics and effects on uterine contractility and cervival ripening in early pregnancy
The results indicate that the peak MPA serum levels seem to correlation with uterine tonus, while the duration of elevated serum levels seems to correlate with the effect on uterine contractility, and the pharmacokinetic profile of misoprostol free acid (MPA) is found to be the most important parameter in terms of inducing contractions. Expand
Effects of Food and Antacid on Oral Absorption of Misoprostol, A Synthetic Prostaglandin E1 Analog
Drug administration with a high‐fat content meal resulted in a marked slowing in the absorption rate without a substantial decrease in the extent, and administration of misoprostol with food could potentially decrease the incidence of systemic side effects by reducing the early high peak plasma concentrations of misiprostol acid. Expand
Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid.
The findings indicate that MPA is displaced from its protein binding sites only by high concentrations of salicylic acid and that this displacement is unlikely to be of clinical significance with the usual therapeutic doses of aspirin. Expand